Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Hematology-Oncology Fellowship, Duke University School of Medicine 2015 - 2018
  • Internal Medicine Residency, University of Maryland School of Medicine 2012 - 2015
  • M.D., Thomas Jefferson University, Sidney Kimmel Medical College 2012
• Research
• 

  Selected Grants

  • A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Abemaciclib to Patients with ER+, HER2-Locally Advanced or Metastatic Breast Cancer awarded by Eli Lilly and Company 2020 - 2025
  • Sermonix SMX 18-001 awarded by Sermonix Pharmaceuticals 2020 - 2025
  • Evaluation of the effects of endocrine therapy and abemaciclib on host and tumor immune cell repertoire/function in advanced ER+/HER2- breast cancer awarded by Eli Lilly and Company 2020 - 2025
  • A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab VersusPlacebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients WithHigh-risk, Estrogen Receptor-Positive (ER+), Human Epider awarded by Bristol-Myers Squibb Company 2019 - 2024
  • Targeting tumor-specific apoptosis regulation in advanced ER+ breast cancer awarded by Department of Defense 2019 - 2022
  • Cancer cell intrinsic and extrinsic actions of steroid hormones in breast tumors awarded by Department of Defense 2018 - 2022
  • TNBC Study awarded by AstraZeneca AB 2017 - 2021
  • Phase II Multicenter Study of Durvalumab (MEDI4736) and Olaparib in PlatinumTreated Advanced Triple Negative Breast Cancer ¿ DORA awarded by Duke University 2018 - 2020
  • Determining the clinical efficacy and predictive biomarkers of mirvetuximab soravtansine (IMGN853) in folate receptor alpha (FRA) expressing, chemotherapy refractory triple negative breast cancer awarded by National Comprehensive Cancer Network 2016 - 2019
• 

  External Relationships

  • Astra zeneca
  • AstraZeneca
  • Daiichi Sankyo Co., Ltd
  • Foundation Medicine
  • Foundation Medicine, Inc.
  • Genomic Health, Inc.,
  • Novartis
  • Sermonix Pharmaceuticals
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Sammons, Sarah, Amanda E. D. Van Swearingen, and Carey K. Anders. “Receptor discordance in breast cancer brain metastases: when knowledge is power.” Neuro Oncol 22, no. 8 (August 17, 2020): 1060–61. https://doi.org/10.1093/neuonc/noaa131.
       Full Text  Link to Item
    • Andreano, Kaitlyn J., Jennifer G. Baker, Sunghee Park, Rachid Safi, Sandeep Artham, Steffi Oesterreich, Rinath Jeselsohn, et al. “The Dysregulated Pharmacology of Clinically Relevant ESR1 Mutants is Normalized by Ligand-activated WT Receptor.” Molecular Cancer Therapeutics 19, no. 7 (July 2020): 1395–1405. https://doi.org/10.1158/1535-7163.mct-19-1148.
       Full Text
    • Hill, Addie, Eutiquio Gutierrez, Jennifer Liu, Sarah Sammons, Gretchen Kimmick, and Mina S. Sedrak. “The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients-Part II: Metastatic Disease.” Drugs Aging 37, no. 5 (May 2020): 349–58. https://doi.org/10.1007/s40266-020-00758-x.
       Full Text  Link to Item
    • Sammons, Sarah, Mina S. Sedrak, and Gretchen G. Kimmick. “The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients-Part I: Early-Stage Disease.” Drugs Aging 37, no. 5 (May 2020): 331–48. https://doi.org/10.1007/s40266-020-00748-z.
       Full Text  Link to Item
    • Sammons, Sarah, Mythili Shastry, Susan Dent, Carey Anders, and Erika Hamilton. “Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR+/HER2- Breast Cancer.” Clin Breast Cancer 20, no. 1 (February 2020): 1–11. https://doi.org/10.1016/j.clbc.2019.06.017.
       Full Text  Link to Item
    • Sammons, S., A. E. D. Van Swearingen, and C. K. Anders. “The Promise of Immunotherapy for Breast Cancer Brain Metastases.” Current Breast Cancer Reports 11, no. 4 (December 1, 2019): 241–47. https://doi.org/10.1007/s12609-019-00335-1.
       Full Text
    • Zhu, Li, Jessica L. Narloch, Sayali Onkar, Marion Joy, Gloria Broadwater, Catherine Luedke, Allison Hall, et al. “Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors.” J Immunother Cancer 7, no. 1 (October 18, 2019): 265. https://doi.org/10.1186/s40425-019-0755-1.
       Full Text  Link to Item
    • Sambade, Maria J., Grace Prince, Allison M. Deal, Dimitri Trembath, Megan McKee, Amy Garrett, Kevin Keith, et al. “Examination and prognostic implications of the unique microenvironment of breast cancer brain metastases.” Breast Cancer Res Treat 176, no. 2 (July 2019): 321–28. https://doi.org/10.1007/s10549-019-05211-1.
       Full Text  Link to Item
    • Dent, Susan, Chiara Melloni, Josee Ivars, Sarah Sammons, and Gretchen Kimmick. “Cardiotoxicities of Modern Treatments in Breast Cancer.” Curr Treat Options Cardiovasc Med 21, no. 7 (June 15, 2019): 34. https://doi.org/10.1007/s11936-019-0738-z.
       Full Text  Link to Item
    • Sammons, Sarah, Noah S. Kornblum, and Kimberly L. Blackwell. “Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer.” Target Oncol 14, no. 1 (February 2019): 1–12. https://doi.org/10.1007/s11523-018-0587-9.
       Full Text  Link to Item
    • Sammons, Sarah, Noah S. Kornblum, and Kimberly L. Blackwell. “Correction to: Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer.” Target Oncol 14, no. 1 (February 2019): 13. https://doi.org/10.1007/s11523-018-0614-x.
       Full Text  Link to Item
    • Force, Jeremy, Lynn J. Howie, Sara E. Abbott, Rex Bentley, P Kelly Marcom, Gretchen Kimmick, Kelly Westbrook, et al. “Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype.” Clin Breast Cancer 18, no. 5 (October 2018): 410–17. https://doi.org/10.1016/j.clbc.2018.02.010.
       Full Text  Link to Item
    • Narloch, Jessica L., S Harrison Farber, Sarah Sammons, Frances McSherry, James E. Herndon, Jenny K. Hoang, Fang-Fang Yin, et al. “Biopsy of enlarging lesions after stereotactic radiosurgery for brain metastases frequently reveals radiation necrosis.” Neuro Oncol 19, no. 10 (October 1, 2017): 1391–97. https://doi.org/10.1093/neuonc/nox090.
       Full Text  Link to Item
    • Sammons, Sarah L., Donna L. Topping, and Kimberly L. Blackwell. “HR+, HER2- Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles.” Curr Cancer Drug Targets 17, no. 7 (2017): 637–49. https://doi.org/10.2174/1568009617666170330120452.
       Full Text  Link to Item
    • Witkiewicz, A. K., A. Dasgupta, S. Sammons, O. Er, M. B. Potoczek, F. Guiles, F. Sotgia, J. R. Brody, E. P. Mitchell, and M. P. Lisanti. “Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers.” Cancer Biology and Therapy 10, no. 2 (July 15, 2010): 135–43. https://doi.org/10.4161/cbt.10.2.11983.
       Full Text

  • Book Sections

    • Sammons, S., M. McNamara, A. K. S. Salama, and J. Crawford. “Immune checkpoint inhibition.” In Side Effects of Medical Cancer Therapy: Prevention and Treatment: Second Edition, 315–53, 2018. https://doi.org/10.1007/978-3-319-70253-7_12.
       Full Text

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.